Literature DB >> 17390261

Tardive dyskinesia.

Karla Soares-Weiser1, Hubert H Fernandez.   

Abstract

This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references. We also contacted the authors of each included trial. All randomized clinical trials that compared different types of active interventions with placebo or no intervention in patients with neuroleptic-induced TD were included in our data. Two reviewers independently applied the selection criteria to all identified references, appraised the methodological quality of each trial, and extracted the relevant data. Relative risks and 95% confidence intervals were estimated using the fixed effect model. More than 500 randomized trials evaluating over 90 different interventions to treat TD were identified. From those, 45 trials were included in the current reviews. None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17390261     DOI: 10.1055/s-2007-971169

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  25 in total

1.  A case of dramatic improvement of severe tardive dyskinesia after switch to aripiprazole.

Authors:  Hannah E Brown; Alice W Flaherty; Donald C Goff; Oliver Freudenreich
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Authors:  Gaurav Jain
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 4.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

Review 5.  Pathological basal ganglia activity in movement disorders.

Authors:  T Wichmann; J O Dostrovsky
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

6.  Tardive dyskinesia: treatment with aripiprazole.

Authors:  Na-Ri Kang; Moon-Doo Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

7.  Two instances of improvement in tardive dyskinesia after administration of aripiprazole in a single patient.

Authors:  Chih-Lun Chen; Han-Wei Chou
Journal:  Prim Care Companion CNS Disord       Date:  2012

8.  Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration.

Authors:  Joseph L McClay; Sarah A Vunck; Angela M Batman; James J Crowley; Robert E Vann; Patrick M Beardsley; Edwin J van den Oord
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-08       Impact factor: 4.147

9.  Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice.

Authors:  James J Crowley; Yunjung Kim; Jin Peng Szatkiewicz; Amanda L Pratt; Corey R Quackenbush; Daniel E Adkins; Edwin van den Oord; Molly A Bogue; Hyuna Yang; Wei Wang; David W Threadgill; Fernando Pardo-Manuel de Villena; Howard L McLeod; Patrick F Sullivan
Journal:  Mamm Genome       Date:  2011-12-30       Impact factor: 2.957

10.  Treatment of Tardive Dyskinesia by tetrabenazine, clonazepam and vitamin E.

Authors:  Himanshu Sharma
Journal:  Indian J Psychiatry       Date:  2009-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.